The reduction in price target by HC Wainwright & Co. suggests a more cautious outlook on Sage Therapeutics' stock value in the short term. Maintaining a Neutral rating indicates that the analyst sees limited upside or downside potential from the current price level. This adjustment could lead to a negative perception among investors, potentially putting downward pressure on the stock price in the short term.